Searched for
CL 2 LICENCE
Covid drug: Natco eyes patent waiverIn its application, Natco has cited the unmet medical needs due to the lack of supply and affordability in light of the grave and life-thre...- Covid drug: Natco eyes patent waiverMaking its case, Natco’s application said Olumiant is not manufactured in India — less than 9,000 tablets were imported in 2019 and 2020, a...
- Hyderabad-based Natco Pharma wants to make Eli Lilly’s Covid drugNatco has sought nod for the manufacture and marketing of baricitinib bulk drug and tablets in 1 to 4 mg versions in India. This move may t...
- Poll heat drying up liquor vends across KarnatakaStrict law enforcement leaves no fizz in the liquor biz before polls, making it one of the driest ever
- Aadhaar, invoice made mandatory for liquor vends in HaryanaMoreover, no liquor sale will be allowed in around 200 villages on the request of panchayats in the state.
- Karnataka penalising bar-cum restaurants for not selling enough liquorThe state excise department has slapped fines, totalling crores of rupees, on over 150 bar-cum-restaurants in Bengaluru, with retrospective...
- FDI during April-February jumps to $37.53 billion: Nirmala SitharamanForeign direct investment (FDI) in India increased to USD 37.53 billion during April-February period of the last fiscal, Parliament was inf...
- What price peace? Bangalore Club drops probe against copThe raid discovered a violation of its CL-4 licence (liquor licence for Clubs) conditions, leading to – on December 2 – a one-month ban on ...
- Cheaper version of cancer drug Dasatinib will have to waitDIPP has shot down a health ministry proposal to consider a government-initiated compulsory licence for cancer drug Dasatinib.
- BDR seeks CL for cancer drug, offers 95% cheaper generic copyThe Mumbai-based firm has applied to the Controller of Patents, Mumbai, seeking the CL for "ease of availability" and "affordability" of th...
- Intellectual board upholds CL to Natco for cancer drugThe IPAB has upheld the compulsory licence issued to Natco Pharma for production and marketing of generic version of cancer drug Nexavar.
- Government suggests doing away with Compulsory License on the basis of priceDOP in the new draft policy said that once patented drugs are regulated, the provision to issue Compulsory License will not be possible
- Best way to expand in India is via partnerships: Adam H Schechter, MerckA strong growth in the antidiabetic drugs market — 25% growth year-on year — has helped Merck boost sales of its blockbuster products.
- The best way to expand in India is through partnerships, says Merck’s SchechterAdam H Schechter, Merck’s executive vicepresident and president, says the global pharma major is committed to India despite the challenges.
- DIPP seeks details on 3 cancer drugs for compulsory licencingDIPP has sought details from the Health Ministry regarding three medicines sold by multinationals in India to make them affordable.
- DIPP examining proposal to issue CL for 3 anti-cancer drugs"The DIPP is expected to ask for some more details from different ministries, including the Health Ministry," the source added.
- US threatens to take India to WTO over Nexavar GenericThe US has threatened to drag India to the WTO for issuing the firstever compulsory licence to a domestic company to manufacture generic ve...
- US ups the ante on Nexavar Generic, threatens to take India to WTOThe US House of Representatives and the US Patent and Trademark Office (USPTO) have threatened to drag India to the WTO.
- Should compulsory licensing be allowed?The CL on sorafenib does not only help cancer patients, it also is a step towards building domestic manufacturing capacity and knowhow in a...
- Natco seeks Pfizer nod for drug cloneIndian Pharma Co claims it can sell HIV drug at one-fifth the price.
Load More
